It is a chronic, disabling brain disorder; it affects about 1.1% of the US population over age 18, in a given year.

Symptoms typically develop in the late teens in men, and a little later in women. Patients suffer the torment of hearing voices that others don’t hear, experience delusions, hallucinations, disordered thinking, feel fearful and paranoid that others are plotting to harm them. This generally leads to social withdrawal, with a downward spiral towards dependence and helplessness.

Current treatments (with anti-psychotics and therapy) may eliminate or reduce many of the symptoms and allow patients to lead independent lives in the community.

Since the first atypical (second-generation) anti-psychotic Clozapine was introduced into clinical practice in the 1970s, Sponsors have seen the need to develop more effective anti-psychotics, with fewer side effects.

Dr. Verghese has been a PI on some pivotal trials since the 1990s. We are currently working on several clinical trials and will be happy to be a resource for patients and caregivers.